ConductScience.org, home

Paper37101772

Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making?

Soria F and 16 others. Eur Urol Open Sci, 2023. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making? Papers, record 37101772. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37101772

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making?
PubMed
Journal
Eur Urol Open Sci
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.77
iCite
Revised in PubMed
2023-04-28
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Soria FFrancesco
2D'Andrea DDavid
3Barale MMaurizio
4Gust KMKilian M
5Pisano FFrancesca
6Mazzoli SSimone
7De Bellis MMatteo
8Rosazza MMatteo
9Livoti SSimone
10Dutto DDaniele
11Lillaz BBeatrice
12Pradere BBenjamin
13Moschini MMarco
14Tamandl DDietmar
15Shariat SFShahrokh F
16Gontero PPaolo
17European Association of Urology Young Academic Urologists Urothelial Carcinoma Working GroupGroup

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References24

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131834509Imaging of sarcopenia: old evidence and new insights.Eur Radiol2020https://conductscience.org/library/papers/31834509PubMed
229289518The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy.Clin Genitourin Cancer2018https://conductscience.org/library/papers/29289518PubMed
321296615Definition and classification of cancer cachexia: an international consensus.Lancet Oncol2011https://conductscience.org/library/papers/21296615PubMed
427104110Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.J Cachexia Sarcopenia Muscle2016https://conductscience.org/library/papers/27104110PubMed
524840856Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality.Cancer2014https://conductscience.org/library/papers/24840856PubMed
621782482Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?Urol Oncol2013https://conductscience.org/library/papers/21782482PubMed
734511303European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).Eur Urol2022https://conductscience.org/library/papers/34511303PubMed
820392703Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.Age Ageing2010https://conductscience.org/library/papers/20392703PubMed
925552207Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection.World J Urol2015https://conductscience.org/library/papers/25552207PubMed
1033419683
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
Eur Urol2021https://conductscience.org/library/papers/33419683PubMed
1132360052European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.Eur Urol2021https://conductscience.org/library/papers/32360052PubMed
1226123787Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma.Dis Esophagus2016https://conductscience.org/library/papers/26123787PubMed
1330259123Molecular markers in bladder cancer.World J Urol2019https://conductscience.org/library/papers/30259123PubMed
1434437899Psoas Muscle Mass can Predict Postsurgical Outcomes in Patients Who Undergo Radical Cystectomy and Urinary Diversion Reconstruction.Urology2021https://conductscience.org/library/papers/34437899PubMed
1529520591Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer.World J Urol2018https://conductscience.org/library/papers/29520591PubMed
1625431236Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.Mod Pathol2015https://conductscience.org/library/papers/25431236PubMed
1723530101Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.J Clin Oncol2013https://conductscience.org/library/papers/23530101PubMed
1823982601Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.Br J Cancer2013https://conductscience.org/library/papers/23982601PubMed
1929276063Is sarcopenia and sarcopenic obesity associated with clinical and pathological outcomes in patients undergoing radical nephroureterectomy?Urol Oncol2018https://conductscience.org/library/papers/29276063PubMed
2024037576Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma.Br J Surg2013https://conductscience.org/library/papers/24037576PubMed

See all 24 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42223672Preclinical evaluation of rBCG-h12: an engineered Bacillus Calmette-Guérin with an enhanced activity against bladder and pancreatic cancers.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42223672PubMed
41945867NQO1-Mediated Anoikis Resistance and Immune Evasion Define a High-Risk Multi-Omic Subtype for Precision Management of T1 High-Grade Bladder Cancer.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41945867PubMed
40731936Sarcopenia in Urothelial Bladder Carcinoma: A Narrative Review.Medicina (Kaunas)2025https://conductscience.org/library/papers/40731936PubMed
38999355Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review.J Clin Med2024https://conductscience.org/library/papers/38999355PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37101772

GET https://conductscience.org/api/papers/v1/37101772/references?page=2